- Poster presentation
- Open Access
Synergistic antitumor interaction between valproic acid and capecitabine in breast cancer
© Terranova-Barberio et al. 2015
- Published: 14 August 2015
- Breast Cancer
- Metastatic Breast Cancer
- Valproic Acid
- Histone Deacetylase Inhibitor
Capecitabine, commonly used in different settings for metastatic breast cancer, is an inactive prodrug that take advantage of the tumor elevated levels of thymidine phosphorylase (TP), a key enzyme for its conversion to 5-florouracil. Potentiation of anticancer activity of capecitabine is required to improve its therapeutic index.
We demonstrated that histone deacetylase inhibitors (HDACi), including the anti-epileptic valproic acid (VPA), induced dose and time-dependent upregulation of TP transcript and protein in breast cancer cells but not in non-tumorigenic MCF-10A cell line. By using siRNA or isoform specific HDACi we demonstrated that HDAC-3 is the main isoform whose inhibition is involved in TP modulation. Combined treatment of HDACi, including VPA, and capecitabine resulted in synergistic/additive antiproliferative and proapoptotic effects in all cell lines tested. TP knockdown experiments demonstrated the crucial role of TP modulation in the synergism observed. The synergistic antitumor effect between VPA and capecitabine was also demonstrated in vivo in a breast cancer xenograft model, but not in xenografts from TP-knocked cells, confirming in vitro data. Overall, this study suggests that the combination of an HDACi, such as valproic acid, and capecitabine, is an innovative antitumour strategy and warrants further clinical evaluation for the treatment of metastatic breast cancer.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.